US · CPIX · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Cumberland Pharmaceuticals Inc. (CPIX) intrinsic value and stock valuation
$5.84as of 2026-11-21 · Mkt cap 113.12M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cumberland Pharmaceuticals Inc. DCF and intrinsic value
InvestorsCraft values CPIX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CPIX’s statements →
Cumberland Pharmaceuticals Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42M | $36M |
| Operating income | -$-2.79M | -$-6.43M | -$-9.55M | -$-5.7M | -$-7.68M |
| Net income | -$-2.84M | -$-6.48M | -$-6.28M | -$-5.57M | -$-3.51M |
| EPSd | -$-189.84K | -$-460.88K | -$-439.16K | -$-382.55K | -$-235.57K |
| Operating cash flow | $4.93M | -$-610K | $6.09M | $8.45M | $6.34M |
| Capital expenditure | -$-100K | -$-180K | -$-450K | -$-2.07M | -$-350K |
| Free cash flow | $4.83M | -$-790K | $5.64M | $6.38M | $5.99M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M |
| Total debt | $10.2M | $20.6M | $18.4M | $21M | $16.1M |
| Net debt | -$-1.26M | $2.61M | $110K | $1.2M | -$-10.98M |
| Total equity | $24.5M | $22.6M | $29.3M | $36M | $42.6M |
| Cash and short-term investments | $11.4M | $18M | $18.3M | $19.8M | $27M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42M | $36M |
| Cost of revenue | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M |
| Gross profit | $37.9M | $31.3M | $33.5M | $32.9M | $27.2M |
| Research and development expenses | $5.57M | $4.82M | $5.83M | $6.69M | $5.68M |
| Selling, general and administrative expenses | $31.1M | $28.2M | $29.1M | $26.8M | $24.8M |
| Other expenses | $4.03M | $4.75M | $8.1M | $5.07M | $4.37M |
| Operating expenses | $40.7M | $37.7M | $43M | $38.6M | $34.9M |
| Cost and expenses | $47.3M | $44.3M | $49.1M | $47.7M | $43.7M |
| Interest income | $480K | $330K | $290K | $100K | $30K |
| Interest expense | $500K | $610K | $670K | $590K | $100K |
| Depreciation and amortization | $5.29M | $6.04M | $8.1M | $5.33M | $4.61M |
| Ebitda | $2.96M | $180K | $2.49M | $330K | -$-860K |
| Operating income | -$-2.79M | -$-6.43M | -$-9.55M | -$-5.7M | -$-7.68M |
| Total other income/expenses, net | -$-30K | -$-30K | $3.27M | $120K | $2.12M |
| Income before tax | -$-2.82M | -$-6.47M | -$-6.28M | -$-5.58M | -$-5.56M |
| Income tax expense | $40K | -$-20K | $50K | $70K | $30K |
| Net income | -$-2.84M | -$-6.48M | -$-6.28M | -$-5.57M | -$-3.51M |
| Weighted average shares outstanding | $15M | $14.1M | $14.3M | $14.6M | $14.9M |
| Weighted average diluted shares outstanding | $15M | $14.1M | $14.3M | $14.6M | $14.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $11.4M | $18M | $18.3M | $19.8M | $27M |
| Net receivables | $16.9M | $11.7M | $9.76M | $13.2M | $6.88M |
| Inventory | $6.23M | $4M | $4.61M | $9.86M | $8.43M |
| Total current assets | $37.1M | $36.5M | $35.7M | $45.9M | $45.7M |
| Property, plant and equipment, net | $8.61M | $6.45M | $7.04M | $5.5M | $1.47M |
| Goodwill and intangible assets | $14.9M | $18.9M | $23.5M | $31.5M | $24.8M |
| Long-term investments | $3.99M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $39.8M | $39.1M | $46.1M | $47.1M | $38.8M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M |
| Accounts payable | $18.6M | $13.9M | $14M | $10.8M | $9.64M |
| Short-term debt | $470K | $5.46M | $350K | $170K | $970K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $36.7M | $31.6M | $28M | $28.6M | $19.3M |
| Long-term debt | $9.71M | $15.1M | $18.1M | $20.8M | $15.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $15.5M | $21.4M | $24.5M | $28.4M | $22.6M |
| Capital lease obligations | $4.94M | $5.3M | $5.64M | $4.76M | $1.06M |
| Total liabilities | $52.3M | $53M | $52.5M | $57M | $41.9M |
| Common stock | $51.7M | $46.8M | $47.1M | $47.5M | $48.5M |
| Retained earnings | -$-26.8M | -$-23.97M | -$-17.49M | -$-11.21M | -$-5.64M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $24.5M | $22.6M | $29.3M | $36M | $42.6M |
| Total investments | $3.99M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $10.2M | $20.6M | $18.4M | $21M | $16.1M |
| Net debt | -$-1.26M | $2.61M | $110K | $1.2M | -$-10.98M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-2.86M | -$-6.48M | -$-6.28M | -$-5.65M | -$-3.6M |
| Depreciation and amortization | $5.29M | $6.04M | $5.77M | $5.33M | $4.61M |
| Stock-based compensation | $410K | $300K | $370K | $450K | $740K |
| Change in working capital | $2.16M | $1.29M | $4.63M | $11M | $8.18M |
| Accounts receivable | -$-5.24M | -$-1.94M | $3.4M | -$-6.12M | $5.5M |
| Inventory | $2.24M | $2.41M | -$-20K | $1.38M | $4.82M |
| Accounts payable | $6.71M | -$-990K | $3.72M | $15.1M | -$-760K |
| Net cash provided by operating activities | $4.93M | -$-610K | $6.09M | $8.45M | $6.34M |
| Investments in property, plant and equipment | -$-180K | -$-180K | -$-450K | -$-2.07M | -$-350K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-13.5M | $0.00 |
| Net cash used for investing activities | -$-4.71M | $60K | -$-110K | -$-13.67M | -$-500K |
| Common stock issued | $5.27M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-260K | -$-580K | -$-740K | -$-1.05M | -$-1.39M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-6.75M | $200K | -$-7.42M | -$-2.06M | -$-3.55M |
| Net change in cash | -$-6.52M | -$-360K | -$-1.44M | -$-7.28M | $2.29M |
| Cash at end of period | $11.4M | $18M | $18.3M | $19.8M | $27M |
| Operating cash flow | $4.93M | -$-610K | $6.09M | $8.45M | $6.34M |
| Capital expenditure | -$-100K | -$-180K | -$-450K | -$-2.07M | -$-350K |
| Free cash flow | $4.83M | -$-790K | $5.64M | $6.38M | $5.99M |
Line items
Line items
Line items
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
- CEO
- A. J. Kazimi
- Employees
- 93
- Beta
- 0.11
Explore
Frequently asked questions
What is the intrinsic value of Cumberland Pharmaceuticals Inc. (CPIX)?
InvestorsCraft does not currently publish an intrinsic value for CPIX. How the IC value is calculated.
Is CPIX undervalued?
InvestorsCraft does not publish an undervaluation signal for CPIX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.